{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:41:45Z","timestamp":1792010505074,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115376","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T09:08:02Z","timestamp":1742548082000},"page":"115376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Reduction in surgical interventions in melanoma"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-6935","authenticated-orcid":false,"given":"Alexander C.J.","family":"van Akkooi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115376_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","article-title":"I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins hospital from June, 1889, to January, 1894","volume":"20","author":"Halsted","year":"1894","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2025.115376_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fonc.2012.00125","article-title":"Breast cancer: from \"maximum tolerable\" to \"minimum effective\" treatment","volume":"2","author":"Veronesi","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJM197709222971202","article-title":"Inefficacy of immediate node dissection in stage 1 melanoma of the limbs","volume":"297","author":"Veronesi","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJM198107023050102","article-title":"Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast","volume":"305","author":"Veronesi","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa030681","article-title":"Excision margins in high-risk malignant melanoma","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial","volume":"378","author":"Gillgren","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115376_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D","article-title":"Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8\u20132.0\u202fmm","volume":"89","author":"Cohn-Cedermark","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/(SICI)1098-2388(199806)14:4<272::AID-SSU2>3.0.CO;2-#","article-title":"Margin of resection in the management of primary melanoma","volume":"14","author":"Cascinelli","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02305762","article-title":"Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial","volume":"3","author":"Karakousis","year":"1996","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/cncr.11272","article-title":"Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick)","volume":"97","author":"Khayat","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00482-9","article-title":"Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial","author":"Hayes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ctrv.2015.10.013","article-title":"Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation","volume":"42","author":"Wheatley","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115376_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ctrv.2016.03.008","article-title":"Response to Wheatley et al., \"Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation\", Cancer Treatment Reviews","volume":"45","author":"Madu","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115376_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2022.10.028","article-title":"The end of wide local excision (WLE) margins for melanoma","volume":"178","author":"Zijlker","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115364","article-title":"Evaluation of Residual Tumour in Wide Local Excision for Melanoma: a nationwide population-based study","author":"Schurink","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115366","article-title":"Reconsidering the surgical approach in cutaneous melanoma: does wide local excisions after a complete diagnostic excision reduce the risk of recurrence?","author":"Stekelenburg","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib18","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","article-title":"1 Versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study","volume":"25","author":"Moncrieff","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2025.115376_bib20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib22","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2025.115376_bib23","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2025.115376_bib24","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab Versus placebo as adjuvant therapy in resected stage IIB or IIC Melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115376_bib25","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.115376_bib26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115376_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.115376_bib28","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib29","article-title":"Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?","volume":"2","author":"van Akkooi","year":"2024","journal-title":"EJC Ski Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1245\/s10434-024-16379-2","article-title":"Society of surgical oncology consensus statement: assessing the evidence for and utility of gene expression profiling of primary cutaneous Melanoma","volume":"32","author":"Bartlett","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib32","article-title":"31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: a SEER collaboration","volume":"7","author":"Bailey","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","volume":"125","author":"Amaral","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","volume":"4","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","article-title":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"140","author":"Eggermont","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","article-title":"Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)","volume":"182","author":"Amaral","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115372","article-title":"Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I\/II melanoma who did not undergo sentinel lymph node biopsy","author":"Amaral","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9606","article-title":"MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma","volume":"40","author":"Hieken","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115376_bib40","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics - Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib41","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115376_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2025.115376_bib43","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115376_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:49:52Z","timestamp":1760640592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"alternative-id":["S0959804925001571"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115376","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in surgical interventions in melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115376"}}